With higher sensitivity to PARP inhibitor treatments, BRCA1/2 positive PCa-s seem to have a different therapeutic sensitivity, suggesting that these patients may benefit from different treatment strategies. The gene discussed is BRCA1; the disease is posterior cortical atrophy.